Cargando…
Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria
BACKGROUND: Emergence of anti-malarial drug resistance and perpetual increase in malaria incidence necessitates the development of novel anti-malarials. Histone deacetylases (HDAC) has been shown to be a promising target for malaria, despite this, there are no HDAC inhibitors in clinical trials for...
Autores principales: | Potluri, Vijay, Shandil, Radha K., Gavara, R., Sambasivam, Ganesh, Campo, Brice, Wittlin, Sergio, Narayanan, Shridhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549214/ https://www.ncbi.nlm.nih.gov/pubmed/33046062 http://dx.doi.org/10.1186/s12936-020-03421-3 |
Ejemplares similares
-
Novel Baicalein-Derived Inhibitors of Plasmodium falciparum
por: Gudla, Chandra Sekhar, et al.
Publicado: (2023) -
Functional characterization of
Candida
albicans Hos2 histone deacetylase
por: Karthikeyan, G, et al.
Publicado: (2014) -
Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases
por: Shandil, Radha Krishan, et al.
Publicado: (2022) -
A novel multistage antiplasmodial inhibitor targeting Plasmodium falciparum histone deacetylase 1
por: Huang, Zhenghui, et al.
Publicado: (2020) -
Histone Deacetylases Play a Major Role in the Transcriptional Regulation of the Plasmodium falciparum Life Cycle
por: Chaal, Balbir K., et al.
Publicado: (2010)